tucidinostat 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
histone deacetylase inhibitors 4973 743420-02-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tucidinostat
  • chidamide
  • epidaza
  • C5055
  • HBI-8000
  • CS-055
  • hiyasta
  • CS055
An orally bioavailable benzamide-type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with potential antineoplastic activity. Chidamide binds to and inhibits HDACs, leading to an increase of acetylation levels of histone proteins. This agent also inhibits the expression of kinases in the PI3K/Akt and MAPK/Ras signaling pathways and may result in cell cycle arrest and the induction of tumor cell apoptosis. This may inhibit tumor cell proliferation in susceptible tumor cells. HDACs, a class of enzymes that deacetylate chromatin histone proteins, are upregulated in many tumor types and play key roles in gene expression. Compared to some other benzamide-type HDAC inhibitors, chidamide is more stable, more resistant to degradation and has a longer half-life.
  • Molecular weight: 390.42
  • Formula: C22H19FN4O2
  • CLOGP: 1.86
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 3
  • TPSA: 97.11
  • ALOGS: -5.22
  • ROTB: 6

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 2014 China Food and Drug Administration (CFDA)
June 23, 2021 PMDA HUYA JAPAN G.K.

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Peripheral T-cell lymphoma indication 109977009
Relapsed or refractory T-cell leukemia-lymphoma indication 110007008 DOID:5603




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.63 acidic
pKa2 11.87 acidic
pKa3 4.26 Basic
pKa4 3.32 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histone deacetylase 2 Enzyme INHIBITOR IC50 6.80 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Histone deacetylase 1 Enzyme INHIBITOR IC50 7.02 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Histone deacetylase 3 Enzyme INHIBITOR IC50 7.17 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Histone deacetylase 10 Enzyme INHIBITOR IC50 7.11 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Histone deacetylase 8 Enzyme INHIBITOR IC50 6.14 SCIENTIFIC LITERATURE
Histone deacetylase 11 Enzyme INHIBITOR IC50 6.37 SCIENTIFIC LITERATURE
Nicotinamide phosphoribosyltransferase Enzyme IC50 5.68 CHEMBL

External reference:

IDSource
87CIC980Y0 UNII
C2932486 UMLSCUI
CHEBI:135918 CHEBI
CHEMBL3621988 ChEMBL_ID
12136798 PUBCHEM_CID
DB06334 DRUGBANK_ID
8305 IUPHAR_LIGAND_ID
C000613826 MESH_SUPPLEMENTAL_RECORD_UI
D10993 KEGG_DRUG
10318 INN_ID
1616493-44-7 SECONDARY_CAS_RN

Pharmaceutical products:

None